Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.39 |
| ▸ | RAF1 | P04049 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1674226 | 0.79 | KMT2A (0.41) | MAPK1ALDH1A1KDM4EALOX15HSD17B10 | |
| SCHEMBL8273121 | 0.78 | SOS1 (0.36) | ALDH1A1KDM4EALOX15HSD17B10MAPT | |
| SCHEMBL23462064 | 0.77 | MAPK14 (0.51) | MAPK1ALDH1A1KDM4EL3MBTL1NPSR1 | |
| SCHEMBL2837643 | 0.77 | ALDH1A1 (0.64) | MAPK1ALDH1A1KDM4EL3MBTL1MAPT | |
| SCHEMBL26985505 | 0.73 | ALDH1A1 (0.48) | ALDH1A1KDM4EALOX15HSD17B10MAPT | |
| SCHEMBL26985518 | 0.73 | GAA (0.36) | ALDH1A1KDM4EMAPTLMNAGAA | |
| SCHEMBL5860698 | 0.70 | KDM4E (0.46) | MAPK1ALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL2109561 | 0.67 | HSD17B10 (0.44) | MAPK1ALDH1A1KDM4EL3MBTL1ALOX15 | |
| SCHEMBL10308321 | 0.67 | MEN1 (0.66) | MAPK1ALDH1A1KDM4EL3MBTL1HSD17B10 | |
| SCHEMBL8907104 | 0.67 | ALDH1A1 (0.44) | ALDH1A1KDM4EHSD17B10LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227453-B1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMA (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2227453-B1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMA (US) | 2016-03-09 | — | — | EP | disclosed |
| US-8519137-B2 | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519137-B2 | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| US-8519137-B2 | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2227453-A2 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009049180-A2 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009049180-A2 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-04-16 | — | — | WO | disclosed |
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-16 | — | — | US | disclosed |
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-16 | — | — | US | disclosed |
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099233-A1 | HETEROARYL AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN3A, SCN2A | MAPK1 4258/4885ALDH1A1 2465/4885KDM4E 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.